Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection

Germany's COVID-19 traffic light is red, and the number of infections is high. But how well is the population protected against the virus variants currently circulating? The new SARS-CoV-2 variant PJ.2.1 has been spreading since May and has long since reached Europe. It traces back to an older viral lineage that has since largely disappeared from the infection landscape. However, the virus likely…

New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection

The new SARS-CoV-2 variant PJ.2.1 has been circulating in Europe since May and is now present in multiple countries, including Canada, the United States, Spain, the Netherlands, and France. Researchers from the German Primate Center and Hannover Medical School studied how well vaccine antibodies can neutralize this variant. They found that PJ.2.1 binds more strongly to the ACE2 receptor, the entry point for SARS-CoV-2 into human cells, than other variants.

Despite this, antibodies from the XFG-adapted mRNA vaccine Comirnaty effectively neutralized PJ.2.1 in laboratory tests. However, the researchers caution that if the variant acquires additional mutations, it could potentially evade the immune response. The study, published in the Journal of Infection and The Lancet Infectious Diseases, suggests that current vaccines provide protection against PJ.2.1, at least for now.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Tuesday 17 November →